An interventional study of Receive traditional medical therapy and transcranial direct current stimulation and Receive traditional medical therapy and sham stimulation in Tinnitus, Subjective, Sudden Deafness and Transcranial Direct Current Stimulation, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-11-27.
Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Tinnitus with a site in China — 18 open to participants now, 18 under way, none of them phase 3. Tinnitus · China.
Among the 32 studies in Tinnitus with a site in China, this one is the 20th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2023, is one of 27 with no phase, reaches primary completion later than 0 of the 17 other live ones, and was the 14th registered.
446 studies on the registry are indexed under Tinnitus; 98 are open to participants now.
Browse Tinnitus studies →18 of the 32 studies in Tinnitus with a site in China are open now. Recruiting first, the newest first:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18+
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18–80
The Third Affiliated hospital of Zhejiang Chinese Medical University · Sites in China
Ages 20–55 · Healthy volunteers
The Third Affiliated hospital of Zhejiang Chinese Medical University · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 49 Tinnitus studies recruiting now, 21 (43%) set no upper age limit and 18 (37%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 86 is above the median of 60 across 370 interventional studies indexed under Tinnitus.
Median enrollment 120 across the 27 interventional studies, 150 across the 5 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 32 has an industry lead sponsor. The 10 most frequent:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 485 studies on the registry; 279 are open to participants now.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University has 8 studies filed under Tinnitus — fewer than ten, so there is no comparison to draw.
5 of the studies in Tinnitus with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07700069Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityAcupuncture Versus Sham Acupuncture for Tinnitus | 2026-12-31 |
| NCT07558837Eye & ENT Hospital of Fudan UniversityFudan Tinnitus Doctor for Tinnitus Management | 2027-05-30 |
| NCT05453019Chinese PLA General HospitalEffects of CI on Tinnitus and Its Symptoms | 2027-07-01 |
| NCT07185061The First Affiliated Hospital with Nanjing Medical UniversityInterventional Treatment of Chronic Tinnitus With Acoustic Stimulation | 2027-07-01 |
| NCT07515482Dan BingManual Acupuncture for Acute Primary Tinnitus | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 32 studies in Tinnitus with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical study is prospective, single-center, randomized, controlled, double-blind clinical trail, which entitled transcranial electrical stimulation for the treatment of acute tinnitus approved by Sun Yat-sen University, and intends to recruit 86 patients with sudden deafness and tinnitus. For acute subjective tinnitus, a common otological disease, the study gave the experimental group patients received tDCS with electrodes positioned over the left temporal cortex for 5 days. To assess the efficacy of conventional medical therapy and tDCS by comparing changes in anterior and posterior tinnitus-related subjective scale scores, such as THI, VAS, BAI, BDI, PSQI, and hearing recovery, in patients who received tDCS, to determine whether tDCS is effective in improving acute tinnitus, and whether it is superior to conventional tinnitus treatment. In addition, the study will continue to follow patients for 1 month,3 months, and 6 months after the end of treatment to observe the long-term sustained efficacy of tDCS. This clinical trail will also evaluate tDCS from the perspective of compliance and safety, and explore the factors affecting the efficacy of this therapy.
Sample size estimation:
On-site recruitment will be conducted in the otolaryngology clinic for eligible patients with sudden deafness and tinnitus, with dedicated personnel to recruit subjects, with a total of at least 86 expected recruitment. In order to retain subjects, staff will tell them about the benefits of inclusion in clinical studies for sudden deafness with tinnitus, and actively add subjects' contact information to provide relevant consulting services for subjects during clinical studies. During follow-up, participants will be provided with a free tinnitus-related assessment test to motivate.
Plan for missing data: Screening failure, i.e. subjects did not meet the inclusion and exclusion criteria, or subjects withdrew informed consent, among other things for reasons why it was not included in this clinical study. Study subjects who failed to screen will be pressed according to their own condition Provide appropriate treatment according to clinical guidelines. This subset of subjects will not be included in clinical studies.
Statistical analysis plan:
When considering the influence of baseline, the continuous variables were analyzed by covariance analysis, and the qualitative indicators were tested by CMH test or logistic regression.
Primary analysis: Using covariance analysis to compare the different changes of THI scores between two groups after 5 days treatment, controlled for age and baseline THI.
Secondary analysis: Using covariance analysis to compare the different changes of VAS, BAI, BDI, PSQI scores between two groups after 5 days treatment, controlled for age and baseline values corresponding to each scale.
Using a repeated measure ANOVA to compare the different changes of THI, VAS, BAI, BDI, PSQI between two groups at 1, 3 and 6 follow-up visits.
Using Chi square test or Fisher exact test to compare the different efficient rate between two groups after 5 days treatment.
Exploratory analysis:
Using multiple linear regression analysis to explore the factors affecting the short-term and long -term efficacy of the two treatments, such as age, hearing loss threshold, tinnitus loudness, tinnitus frequency and so on.
Using Independent two sample t-test or nonparametric analysis to compare the differences in EEG- or fMRI-related indicators between two groups.
Safety analysis:
Using Pearson's chi-square test to compare the difference of adverse event incidence rate between two groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
intravenous methylprednisolone infusion (dose of 1 mg/kg/day, maximum 60 mg/day) for 5 to 10 days. Patients included in this study were routinely examined and tested for audiometry, including otoscopy, pure tone audiometry, acoustic impedance, brainstem evoked potential, and tinnitus detection. After completion, the 32-guide EEG collector from Bricon was used to collect changes in neural activity in all subjects.
Device: Receive traditional medical therapy and transcranial direct current stimulation
Similarly, intravenous methylprednisolone infusion (dose of 1 mg/kg/day, maximum 60 mg/day) for 5 to 10 days. By controlling the tDCS stimulator to mimic only the first 30 seconds of tDCS stimulation, after 30 seconds of pathway resistance control, so that the stimulation intensity is below the threshold, without giving real stimulation, in this process, the position of the stimulation target is not changed, and the rest of the operation is the same.
Device: Receive traditional medical therapy and sham stimulation
Equipment used: Bricon tDCS stimulator, high-precision electrode stimulation method Stimulant dose: 1.5mA Stimulation time: 20 minutes/time, continuous treatment for 5 days Stimulation course: 5 days/course Stimulation target: left auditory cortex area, i.e., under system 10-20, left T3 position.
By controlling the tDCS stimulator to mimic only the first 30 seconds of tDCS stimulation, after 30 seconds of pathway resistance control, so that the stimulation intensity is below the threshold, without giving real stimulation, in this process, the position of the stimulation target is not changed, and the rest of the operation is the same.
Changes in Tinnitus Handicap Inventory (THI) scores for short-term efficacy assessment
Difference in the change of THI scores between two groups after 5 days treatment. The THI evaluates the severity of tinnitus in terms of emotion and function. The global scores of THI range from 0 (no disability) to 100 (serve disability).
Time frame: From baseline to after 5 days treatment
Changes in scores of Visual Analog Scale (VAS) for short-term efficacy assessment
Difference in the change of VAS scores between two groups after 5 days treatment. The total VAS scores range from 0 (negligible) to 10 (too noisy to tolerate), reflecting the loudness of tinnitus patients feel.
Time frame: From baseline to after 5 days treatment
Changes in scores of Beck Anxiety Inventory (BAI) for short-term efficacy assessment
Difference in the change of BAI scores between two groups after 5 days treatment. The total BAI scores range from 0 (normal) to 63 (serve anxiety), reflecting the degree of anxiety.
Time frame: From baseline to after 5 days treatment
Changes in scores of Beck Depression Inventory (BDI) for short-term efficacy assessment
Difference in the change of BDI scores between two groups after 5 days treatment. The total BDI scores range from 0 (normal) to 63 (serve depression), reflecting the degree of depression.
Time frame: From baseline to after 5 days treatment
Changes in scores of Pittsburgh sleep quality index (PSQI) for short-term efficacy assessment
Difference in the change of PSQI scores between two groups after 5 days treatment. The total PSQI scores range from 0 (sleep well) to 21 (quite poor sleep), reflecting the sleep quality.
Time frame: From baseline to after 5 days treatment
Changes of Tinnitus Handicap Inventory (THI) scores in the two groups for long-term efficacy assessment
Difference in changes of THI between two groups from 1-month follow-up visit to 6-month follow-up visit. The THI evaluates the severity of tinnitus in terms of emotion and function. The global scores of THI range from 0 (no disability) to 100 (serve disability).
Time frame: From 1-month follow-up visit to 6-month follow-up visit
Changes of Visual Analog Scale (VAS) scores in the two groups for long-term efficacy assessment
Difference in changes of VAS between two groups from 1-month follow-up visit to 6-month follow-up visit. The total VAS scores range from 0 (negligible) to 10 (too noisy to tolerate), reflecting the loudness of tinnitus patients feel.
Time frame: From 1-month follow-up visit to 6-month follow-up visit
Changes of Beck Anxiety Inventory (BAI) scores in the two groups for long-term efficacy assessment
Difference in changes of BAI between two groups from 1-month follow-up visit to 6-month follow-up visit. The total BAI scores range from 0 (normal) to 63 (serve anxiety), reflecting the degree of anxiety.
Time frame: From 1-month follow-up visit to 6-month follow-up visit
Changes of Beck Depression Inventory (BDI) scores in the two groups for long-term efficacy assessment
Difference in changes of PSQI between two groups from 1-month follow-up visit to 6-month follow-up visit. The total BDI scores range from 0 (normal) to 63 (serve depression), reflecting the degree of depression.
Time frame: From 1-month follow-up visit to 6-month follow-up visit
Changes of Pittsburgh sleep quality index (PSQI) scores in the two groups for long-term efficacy assessment
Difference in changes of PSQI between two groups from 1-month follow-up visit to 6-month follow-up visit. The total PSQI scores range from 0 (sleep well) to 21 (quite poor sleep), reflecting the sleep quality.
Time frame: From 1-month follow-up visit to 6-month follow-up visit
The effective rate of relieving sudden deafness with tinnitus in the two groups
Group effective rate = number of patients in each group who completed 5 days of treatment and whose THI score decreased by ≥ 7 points / number of patients in each group who completed 5 days of treatment.
Time frame: From baseline to after 5 days treatment
The difference of functional connectivity based on resting state electroencephalogram (EEG) between the two groups
The difference of functional connectivity based on resting state electroencephalogram (EEG) in the two groups from 1-month follow-up visit to 6-month follow-up visit. The functional connectivity is defined as the correlation between two different brain regions based on coherence or phase synchronization.
Time frame: From 1-month follow-up visit to 6-month follow-up visit
The difference of effective connectivity based on resting state electroencephalogram (EEG) between the two groups
The difference of effective connectivity based on resting state electroencephalogram (EEG) in the two groups from 1-month follow-up visit to 6-month follow-up visit. The effective connectivity is defined as the directed functional connectivity between two brain regions based on granger causality analysis.
Time frame: From 1-month follow-up visit to 6-month follow-up visit
The difference of functional connectivity based on functional magnetic resonance imaging (fMRI) between the two groups
The difference of functional connectivity based on functional magnetic resonance imaging (fMRI) in the two groups from 1-month follow-up visit to 6-month follow-up visit. The functional connectivity is defined as the Pearson's correlation between two different brain regions.
Time frame: From 1-month follow-up visit to 6-month follow-up visit
The difference of effective connectivity based on functional magnetic resonance imaging (fMRI) between the two groups
The difference of effective connectivity based on functional magnetic resonance imaging (fMRI) in the two groups from 1-month follow-up visit to 6-month follow-up visit. The effective connectivity is defined as the directed functional connectivity between two brain regions based on granger causality analysis.
Time frame: From 1-month follow-up visit to 6-month follow-up visit
Incidence of treatment-related adverse events
Treatment related adverse events in two groups include: auditory system related adverse reactions caused by treatment, such as auricle burn, earache, hearing loss, tinnitus aggravation, and head injury Dizziness, headache, palpitation, vomiting and other non auditory system related adverse reactions. Incidence of adverse events = number of treatment-related adverse events during treatment / total number of participants in treatment.
Time frame: From baseline to 6-month follow-up visit
Start is estimated for Nov 2023; primary completion for Aug 2024, 9 months later.
Of 134 non-industry interventional studies with no phase under Tinnitus, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 9 months is below that.
Counting every sponsor, half of 153 studies reached it within 17 months; a quarter within 10 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University →